Accession Therapeutics Limited
Julia D. has extensive experience in the field of clinical operations, with over 20 years of work experience. Julia'smost recent position was as a Senior Director of Clinical Operations at Accession Therapeutics Limited, starting in March 2023. Prior to that, they worked as a Director of Clinical Scientist at Adaptimmune from July 2021 to March 2023. Julia also held various roles at AstraZeneca, including Global Clinical Operations Director and Associate Director Study Management, from 2016 to 2021. Before that, they worked at Mundipharma Research Limited, where they held positions such as Senior Pharmacological & Translational Science Manager, Magazine Editor, Early Innovation Manager, and Senior Clinical Project Manager. Additionally, Julia worked as a Trainer at the Association of Clinical Research Professionals and held Trial Manager positions at Queen Mary University of London, Institute of Psychiatry, Psychology & Neuroscience, and The Institute of Cancer Research. Julia also gained experience as a Clinical Trial Monitor /CRA at UCL and as a Study Site Coordinator/Research Psychologist at St George's University Hospitals NHS Foundation Trust. Julia’s work experience demonstrates their expertise in clinical operations and research management.
Julia D. obtained their Bachelor of Science (BSc) degree in Psychology from the University of Portsmouth between 1994 and 1997. Later, in 2013 to 2014, they pursued a Master's Degree in Sport and Exercise Psychology from the same university.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.